Are Royal Dutch Shell Plc, BT Group plc And GlaxoSmithKline plc Brilliant Bargains Or Value Traps?

Royston Wild discusses whether investors should be sucked in by low prices over at Royal Dutch Shell Plc (LON: RDSB), BT Group plc (LON: BT.A) and GlaxoSmithKline plc (LON: GSK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at the investment prospects of three cut-price FTSE candidates.

Royal Dutch Shell

Shares in Royal Dutch Shell (LSE: RDSB) have rattled steadily lower since last summer due to fears over the future of the crude price. Indeed, the stock has shed a fifth of its value during the past six months alone, prompting many to engage in a spot of bargain-hunting — the fossil fuel colossus has risen 16% in the past seven days, thanks in some part to the military escalation in Syria.

Conventional metrics suggest that Shell is quite the bargain at the current time. Despite a projected 33% earnings decline in 2015, the company trades on an earnings multiple of just 12.4 times, comfortably below the benchmark of 15 times that represents brilliant value. And an estimated dividend of 186 US cents per share, although down from 188 cents in 2014, creates a gigantic yield of 7.6%.

Still, I believe the waves of negative news hitting the oil sector threatens to send crude sinking again — just today the IMF cut its 2015 global growth forecasts to 3.1% from 3.3% previously, the lowest reading since 2009. With US and Chinese inventories remaining chock-full of material, and total supply levels continuing to tick higher, I believe earnings — and consequently dividends — at Shell are in danger of trending much, much lower.

BT Group

Unlike Shell, I reckon that telecoms giant BT (LSE: BT-A) is a shrewd pick for value seekers. Like the oil producer, BT has seen its share price sink in recent months, and the business has fallen 10% from the record peaks around 480p struck in July. But thanks to the massive investment in its ‘quad play’ capabilities, I reckon the stock should start trekking higher again sooner rather than later.

The London firm’s decision to take on the might of Sky is paying off handsomely, and revenues at its BT Consumer arm ticked 3% higher during April-June, to £1.1bn, maintaining the steady momentum of recent quarters. The company’s BT Sport channels are going down a treat with couch potatoes up and down the land, while its extensive fibre-laying programme is enjoying terrific traction, a key battleground in the entertainment services segment.

The City expects the vast cost of these measures to push earnings 3% lower in the 12 months to March 2015, although this still produces a decent P/E ratio of just 13.5 times. And BT’s solid long-term growth prospects are anticipated to keep the dividend rising, resulting in a payment of 14p per share for the current year alone and creating a chunky 3.3% yield. I expect BT to become a very lucrative share pick in the years to come.

GlaxoSmithKline

I believe similar bullishness can be attached to pills play GlaxoSmithKline (LSE: GSK), too. The company has thrown the kitchen sink at rejuvenating its product pipeline — it currently has 40 new molecular entities (or NMEs) at the late-stage testing phase, and announced plans to file an application for its Relvar Ellipta treatment in Japan early in 2016 in September. The drug is used to battle the effects of chronic obstructive pulmonary disease (or COPD).

GlaxoSmithKline also received positive Phase III data for its Triumeq HIV treatment last month, as well as a positive opinion from the European Medicines Agency recommending marketing authorisation for its Nucala asthma treatment. Shares have failed to react strongly thanks to enduring fears over patent losses, however, and GlaxoSmithKline has surrendered 17% of its value during the past six months alone.

 But I believe that current weakness provides a great opportunity for savvy investors to pile in. GlaxoSmithKline is expected to endure a 21% earnings slide in 2015 due to the aforementioned exclusivity losses across key labels, although the bottom line is expected to bounce from next year. And this year’s estimate provides a very-decent P/E ratio of 16.8 times. Furthermore, I reckon the firm will make good on a dividend of 80p per share through to 2017, yielding an exceptional 6.1%.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »